Article Text

PDF

Comparative efficacy and tolerability of first-generation and newer-generation antidepressant medications for depressive disorders in children and adolescents: study protocol for a systematic review and network meta-analysis
  1. Xinyu Zhou1,
  2. Bin Qin1,
  3. Craig Whittington2,
  4. David Cohen3,
  5. Yiyun Liu1,
  6. Cinzia Del Giovane4,
  7. Kurt D Michael5,
  8. Yuqing Zhang1,
  9. Peng Xie1
    1. 1Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
    2. 2Research Department of Clinical, Educational and Health Psychology, University College London, London, UK
    3. 3Department of Child and Adolescent Psychiatry, AP–HP, Hôpital Pitié–Salpétrière, Institut des Systèmes Intelligents et de Robotiques (ISIR), Centre National pour la Recherche Scientifique, Université Pierre et Marie Curie, Paris, France
    4. 4Department of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio, Emilia, Modena, Italy
    5. 5Department of Psychology, Appalachian State University, Boone, North Carolina, USA
    1. Correspondence to Professor Peng Xie; xiepeng973{at}126.com

    Abstract

    Introduction Depressive disorders are among the most common psychiatric disorders in children and adolescents, and have adverse effects on their psychosocial functioning. Questions concerning the efficacy and safety of antidepressant medications in the treatment of depression in children and adolescents, led us to integrate the direct and indirect evidence using network meta-analysis to create hierarchies of these drugs.

    Methods and analysis Seven databases with PubMed, EMBASE, the Cochrane Library, Web of Science, CINAHL, LiLACS and PsycINFO will be searched from 1966 to December 2013 (updated to May, 2015). There are no restrictions on language or type of publication. Randomised clinical trials assessing first-generation and newer-generation antidepressant medications against active comparator or placebo as acute treatment for depressive disorders in children and adolescents (under 18 years of age) will be included. The primary outcome for efficacy will be mean improvement in depressive symptoms, as measured by the mean change score of a depression rating scale from baseline to post-treatment. The tolerability of treatment will be defined as side effect discontinuation, as defined by the proportion of patients who discontinued treatment due to adverse events during the trial. We will also assess the secondary outcome for efficacy (response rate), acceptability (all-cause discontinuation) and suicide-related outcomes. We will perform the Bayesian network meta-analyses for all relative outcome measures. Subgroup analyses and sensitivity analyses will be conducted to assess the robustness of the findings.

    Dissemination The network meta-analysis will provide useful information on antidepressant treatment for child and adolescent depression. The results will be disseminated through peer-reviewed publication or conference presentations.

    Trial registration number PROSPERO CRD42015016023.

    Statistics from Altmetric.com

    Strengths and limitations of this study

    • This Bayesian network meta-analysis can integrate direct evidence with indirect evidence from multiple treatment comparisons to estimate the interrelations across all treatments.

    • We will comprehensively assess the efficacy, tolerability, acceptability and suicide-related outcomes of first-generation and newer-generation antidepressant medications for depression in children and adolescents.

    • Several subgroup and sensitivity analyses will address some clinically relevant questions.

    • This method comprehensively synthesises data to provide a clinically useful summary that can guide treatment decisions and guideline development.

    Background

    Depressive disorders in children and adolescents are a major public health problem, demonstrated by the disorders ranking as the third most important in the estimation of disease burden.1 The prevalence of experiencing at least one episode of major depression before adulthood is estimated to be approximately 1–2% for children (6–12 years old), and 2–5% for adolescents (13–18 years old).2 The course of major depression in young people is often characterised by frequent recurrence, protracted episodes and comorbid psychiatric disorders.3 The consequences of an untreated episode of major depression in young people are likely to be serious impairment in social functioning, for example, poor school achievement, or relational problems with family members and peers.4 A report from the American Academy of Child and Adolescent Psychiatry (AACAP) suggested that depression is responsible for over 500 000 suicide attempts by children and adolescents a year, with most of this group diagnosed with treatable forms of mental illness.5 ,6 Thus, early recognition, diagnosis and treatment of depression in children and adolescents is an important strategy for curbing the rising rate of youth suicide, seen in many developed and advanced developing nations.7

    Since the late 1960s, first-generation antidepressants, for example, tricyclic antidepressant (TCA) drugs, have been used to treat depressive symptoms in young patients.8 In the US, the use of antidepressant medication in children and adolescents grew 3–10-fold between 1987 and 1996.9 The efficacy of TCAs has been investigated in 13 randomised placebo-controlled trials,10 which showed marginal evidence to support the use of TCAs in the treatment of depression in only adolescents. However, methodological deficiencies in these trials, including small sample sizes and diagnostic heterogeneity, restrict statistical inference and generalisability of the findings. At the same time, cardiovascular effects and overdose-related mortality associated with TCA use have greatly limited their utility in clinical practice.11 ,12 Nevertheless, the TCA nortriptyline is still approved by the Food and Drug Administration (FDA) for the treatment of depression in adolescents and adults.13

    In recent decades, newer-generation antidepressants, including second-generation antidepressants (eg, selective serotonin reuptake inhibitors (SSRIs)) and third-generation antidepressants (eg, serotonin–norepinephrine reuptake inhibitors (SNRIs)), have been widely used for the treatment of depression in children and adolescents.14 The frequency of prescription of SSRIs and SNRIs in children and adolescents has progressively increased.15 In European countries, there has been a doubling of SSRI use over a 4-year period.16 However, only fluoxetine was approved by the US FDA for treating depression in children and adolescents in January 2003.17 In the same year, concerns about the increased risk of suicide and suicide attempts with SSRIs were first raised.18 In September 2004, the FDA cautioned practitioners in the use of antidepressant medications in children and adolescents.19 Similar warnings were issued by other health regulatory agencies.20–22 Thus, concerns about this issue have refocused attention on the question of how effective antidepressant medications are in treating youth depression.

    Nonetheless, currently, no published meta-analysis has combined direct and indirect evidence for the use of antidepressant medications on children and adolescents, though it is an important study to perform, given the conflicting results regarding the efficacy and tolerability of various antidepressant medications in this age group, and lack of head-to-head trials of such drugs.23–25 For these reasons, we will employ a network meta-analysis—a methodological approach that allows the simultaneous comparison of multiple psychotherapeutic interventions within a single analysis, while preserving randomisation.26 This approach will be used to integrate direct evidence (from studies directly comparing interventions) with indirect evidence (information about two treatments derived via a common comparator) from multiple treatment comparisons to estimate the interrelations across all treatments.27 We have previously compared the efficacy and acceptability of psychotherapies for depression in children and adolescents,28 and the augmentation agents for treatment-resistant depression in adults29 in this way. The aim of the network meta-analysis of randomised controlled trials (RCTs) is to systematically reanalyse the efficacy, tolerability, acceptability and suicide risk of both first-generation and newer-generation antidepressant medications against active comparator or control conditions, in the treatment of child and adolescent depression.

    Methods

    Criteria for included studies

    Types of studies

    Any prospective RCTs, including cross-over design and cluster randomised trials, will be included. However, quasi-randomised trials (eg, those allocating using alternate days of the week) will be excluded. Trials with sample sizes smaller than 10 will be excluded in this review.

    Types of participants

    Children and adolescents (aged from 6 to 18 years when they initially enrolled in the trials) with a primary diagnosis of current major depressive disorder according to standardised diagnostic interviews, for example, the Diagnostic and Statistical Manual of Mental Disorders (DSM)30–32 or the International Classification of Diseases (ICD),33 ,34 will be included. Where a trial contains a portion of participants who are over 18 years of age, we will contact the trial authors in order to obtain data for only those participants within our age range. We will exclude trials focusing on child or adolescent bipolar disorder, but will include trials involving patients with comorbid general psychiatric disorders, such as attention deficit hyperactivity disorder, anxiety disorder and substance-related disorder. Also, we will not exclude trials in which participants have a diagnosis of psychotic depression; these participants will be considered within a separate subgroup analysis. However we will exclude trials in which participants have a diagnosis of treatment-resistant depression, because these patients tend to have a different treatment response compared with patients with non-resistant depression.

    Types of interventions

    RCTs comparing any first-generation and newer-generation antidepressant drug against active comparator or placebo for treatment of depression in children and adolescents will be included. Trials comparing the same type of antidepressant but at different therapeutic dose (fixed or flexible dose) and different treatment duration will be considered as the same node in the network analysis. We will exclude trials involving combination therapy (ie, combination of antidepressant medications, combination of antidepressant medication with psychotherapy, or other non-psychotherapeutic interventions); however, trials will be considered as eligible if the concomitant psychotherapy is not predefined in the study.

    Types of outcome measures

    The acute phase will be defined as from 4 to 16 weeks, and if a trial presents data beyond 16 weeks or for more than one time period within our predefined acute phase periods, we will take the 8-week or close to 8-week time point.35 We will exclude trials with treatment duration of <4 weeks. Where depression symptoms are measured using more than one depression scale in a trial, we will extract data from the depressive scales on the basis of a hierarchy of rating scales. This hierarchy will be based on psychometric properties and appropriateness for use with children and adolescents, and for consistency of use across trials (referred from the Hetrick14 et al study) (table 1). The Children's Depression Rating Scale Revised (CDRS-R)36 is adapted for children and adolescents from the Hamilton Depression Rating Scale (HAMD),37 a tool validated and commonly used in adult populations.38 Both the CDRS-R and HAMD have good reliability and validity.38 The Beck Depression Inventory (BDI)39 and the Children's Depression Inventory (CDI)40 are the most commonly used among depression symptom severity self-rated scales and are ranked second highest in the hierarchy.

    1. Overall efficacy

      • The primary outcome for efficacy will be mean improvement in depressive symptoms, as measured by the mean change score of depression rating scales (self-rated or assessor-rated) from baseline to end point.

      • The secondary outcome for efficacy will be response in depressive symptoms, as estimated by the proportion of patients who achieved a decrease of a certain percentage (eg, a reduction of 50% or more) in depression rating score.41 When ‘response’ is not reported, we will use ‘remission’, if available. Remission will be defined as the proportion of patients who achieved a depression rating score below the published threshold (eg, CDRS-R≤28).41

    2. Overall tolerability

    Table 1

    Hierarchy of depression symptom severity measurement scales

    The tolerability of treatment will be defined as side effect discontinuation in this review, as defined by the proportion of patients who discontinued treatment due to adverse events during the study.

    • Overall acceptability

    The acceptability of treatment will be defined as all-cause discontinuation, as measured by the proportion of patients who discontinued treatment (during the delivery of the intervention) up to the post-intervention time point.

    • Suicide-related outcomes

    Suicide-related dichotomous and continuous outcomes will be measured. If data are available, we will extract the number of participants with suicide-related events (combined suicidal ideation and suicidal behaviour) during the acute treatment, as measured on a standardised, validated and reliable rating scale, or reported cases of suicidality.42 In addition, we will also collect data on suicidal ideation as a continuous outcome where a standardised, validated and reliable rating scale, such as the Suicidal Ideation Questionnaire-Junior High School version (SIQ-JR),43 has been used.

    Data sources and search strategy

    Seven electronic databases (PubMed, EMBASE, the Cochrane Library, Web of Science, CINAHL, LiLACS and PsycINFO) will be searched from 1966 to December 2013 (updated to May, 2015), with Medical Subject Headings (MeSH) and text words: ‘depress*’ or ‘dysthymi*’ or ‘mood disorder*’ or ‘affective disorder*’ and ‘selective serotonin reuptake inhibitor*’ or ‘SSRIs’ or ‘serotonin norepinephrine reuptake inhibitor*’ or ‘SNRIs’ or ‘noradrenergic and specific serotonergic antidepressants’ or ‘NaSSA’ or ‘citalopram’ or ‘fluoxetine’ or ‘paroxetine’ or ‘sertraline’ or ‘escitalopram[’ or ‘fluvoxamine’ or ‘venlafaxine’ or ‘duloxetine’ or ‘milnacipran’ or ‘reboxetine’ or ‘bupropion’ or ‘mirtazapine’ or ‘tricyclic’ or ‘amersergide’ or ‘amineptine’ or ‘amitriptyline’ or ‘amoxapine’ or ‘butriptyline’ or ‘chlorpoxiten’ or ‘clomipramine’ or ‘clorimipramine’ or ‘demexiptiline’ or ‘desipramine’ or ‘dibenzipin’ or ‘dothiepin’ or ‘doxepin’ or ‘imipramine’ or ‘lofepramine’ or ‘melitracen’ or ‘metapramine’ or ‘nortriptyline’ or ‘noxiptiline’ or ‘opipramol’ or ‘protriptyline’ or ‘quinupramine’ or ‘tianeptine’ or ‘trimipramine’ and ‘adolesc*’ or ‘child*’ or ‘boy*’ or ‘girl*’ or ‘juvenil*’ or ‘minors’ or ‘paediatri*’ or ‘pediatri*’ or ‘pubescen*’ or ‘school*’ or ‘student*’ or ‘teen*’ or ‘young’ or ‘youth*’. Also, ClinicalTrials.gov, WHO's trial portal, and US FDA reports will be reviewed. There are no restrictions on language or type of publication. Additional studies will be searched in the reference lists of all identified publications including relevant meta-analyses and systematic reviews. All relevant authors and principal manufacturers will be contacted to supplement incomplete reports of the original papers or to provide new data for unpublished trials.

    Study selection

    Two reviewers (BQ and YL) will independently scan citations at the title/abstract level identified from the search strategies and then obtain potentially relevant studies in full text, and determine whether to include them by the same eligibility criteria. Besides, the references of relevant reviews and included trials will also be checked by the two reviewers. The reasons for exclusion of trials will be reported in the characteristics of excluded studies tables. Any disagreements will be resolved by a third review author (XZ).

    Data extraction and risk of bias assessment

    Two independent reviewers (YL, BQ) will independently extract the key trial parameters using a standardised data abstraction form and assess the risk of bias. The standardised data extraction forms will include the trial characteristics (eg, first listed author, publication year, journal, country, institution and sponsor), patient characteristics (eg, diagnostic criteria for depression, the type of patients, the number of patients, level of depressive symptoms, comorbidities, the age of patients and the gender of patients), intervention details (eg, antidepressant type, dose of antidepressant and the duration of treatment) and outcome measures (efficacy, tolerability, acceptability and suicide-related outcome). The risk of bias in trials will be assessed by the Cochrane risk of bias tool.42 Trials attracting a rating of high risk of bias in one or more domains will be considered as ‘high risk’, low risk of bias in all domains as ‘low risk’ and one or more unclear risk of bias in each domain as ‘unclear risk’.42 Any disagreements will be resolved by a third review author (XZ). In addition, we will calculate the inter-rater reliability of the two raters.

    Data synthesis and analysis

    We will perform Bayesian network meta-analysis to compare the relative outcomes of different antidepressant medications and placebo with each other from the median of the posterior distribution.26 ,27 The pooled estimates of standardised mean difference (SMD) with 95% credible intervals (CrIs) will be calculated for the continuous outcomes; and ORs with 95% CrIs will be calculated for the categorical outcomes. The SMD is that the difference in means (MD) of change scores between the two groups divided by the pooled SD of the measurements, with a negative SMD value, indicates greater symptomatic relief. In the presence of minimally informative priors, CrIs can be interpreted similarly to CIs, and at conventional levels of statistical significance a two sided p<0.05 can be assumed if 95% CrIs do not include 0. If means and SDs are not provided, we will calculate them from the p value or other statistical indices as described elsewhere.44 ,45 Results from intention-to-treat analysis (ITT) or modified ITT will be preferred over results from completer analyses, while we will also consider the data set for the means and SDs that are presented in the literature.

    The pooled estimates will be obtained using the Markov Chains Monte Carlo method. Two Markov chains will be run simultaneously with different arbitrarily chosen initial values. To ensure convergence, trace plots and the Brooks-Gelman-Rubin statistic will be assessed.46 Convergence will be found to be adequate after running 50 000 samples for both chains. These samples will be then discarded as ‘burn-in’, and posterior summaries will be based on 100 000 subsequent simulations. The node splitting method will be used to calculate the inconsistency of the model, which separates evidence on a particular comparison into direct and indirect evidence.47 Probability values will be summarised and reported as surface under the cumulative ranking curve (SUCRA) and rankograms, a simple transformation of the mean rank used to provide a hierarchy of the treatments and accounts for both the location and the variance of all relative treatment effects.48 Network meta-analysis will be performed using the WinBUGS software package (V.1.4.3, MRC Biostatistics Unit, Cambridge, UK) with random-effects models for multiarm trials. The other analyses will be performed and presented by the Stata V.11.0 and R 2.11.1 software packages.

    Subgroup analyses

    The antidepressant medications will be coded according to clinical characteristics, risk of bias and sample size. We will conduct the subgroup analyses of data in primary outcome for efficacy. We will perform the following subgroup analyses by using the meta-regression model, and calculate Somer's D (a correlation coefficient for a dichotomous and an ordinal variable):49 (1) sex ratio (male-to-female ratio >1 vs male-to-female ratio <1); (2) age group; (3) treatment duration; (4) severity of depressive symptom (mild-to-moderate vs moderate-to-severe); (5) comorbid general psychiatric disorders (with vs without comorbidity); (6) risk of bias (‘high risk’ literature vs ‘unclear and low risk’ literature); (7) sample size; (8) company sponsor (with vs without sponsor); and (9) the type of trials (published literature vs unpublished literature). When there is the limitation of a small number of comparisons for some potential modifiers in carrying out subgroup analyses on these variables, we will perform the sensitivity analyses by omitting specific trials from the overall analysis.

    Other analyses

    Funnel plot analyses will be performed to check for publication bias. Moreover, we will carry out meta-regression analyses to investigate the effect of sponsorship or year published on outcome estimate.

    Ethics and dissemination

    This network meta-analysis does not need ethical approval, as data used here are not individual or private. The analysis will be published in a peer-reviewed journal. The results will provide a general overview, and evidence of efficacy and safety of antidepressant medications for depression in children and adolescents. The results will also have implications for clinical practice and further research.

    References

    View Abstract

    Footnotes

    • XZ and BQ contributed equally.

    • Collaborators Andrea Cipriani and Sarah E Hetrick.

    • Contributors XZ and BQ conceived the study and drafted the protocol. XZ and PX wrote the first draft of the manuscript. KDM, CW and DC assisted in protocol design and revision. YL and YZ participated in the search strategy development. CDG and BQ participated in the design of data synthesis and analysis. All the authors have approved the publication of the protocol.

    • Funding This work is supported by the National Basic Research Program of China (973 Program) (grant number 2009CB918300).

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.